Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 26,200 shares, an increase of 37.2% from the February 13th total of 19,100 shares. Based on an average trading volume of 53,400 shares, the short-interest ratio is presently 0.5 days.
Analyst Ratings Changes
Separately, Raymond James reissued a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research report on Monday, February 3rd.
Get Our Latest Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
- Five stocks we like better than Medexus Pharmaceuticals
- What Investors Need to Know to Beat the Market
- 3 Must-Own Stocks to Build Wealth This Decade
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.